Have a personal or library account? Click to login
Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome Cover

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 1 (March 2022)
By: Hasan H. Yeter,  Ulver Derici,  Turgay Arinsoy,  Kadriye Altok,  Yasemin Erten and  Galip Guz  
Open Access
|Mar 2022
DOI: https://doi.org/10.2478/rjim-2021-0034 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Journal RSS Feed
Language: English
Page range: 56 - 65
Submitted on: Jun 22, 2021
|
Published on: Mar 17, 2022
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
atypical hemolytic uremic syndrome,
eculizumab,
therapeutic plasma exchange,
discontinuation,
prognosis
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Cardiology,
Gastroenterology,
Rheumatology

© 2022 Hasan H. Yeter, Ulver Derici, Turgay Arinsoy, Kadriye Altok, Yasemin Erten, Galip Guz, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 60 (2022): Issue 1 (March 2022)Next article